Guest guest Posted July 16, 2008 Report Share Posted July 16, 2008 XOMA to Present Data Of Phase 1 Type 2 Diabetes Study www.rttnews.com/Content/BreakingNews.aspx?Node=B1 & Id=654991%20 & Category=Breaking\ %20News 7/15/2008 3:16 PM ET (RTTNews) - Tuesday, biopharmaceutical company XOMA Ltd. said it would present results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes examining the safety and pharmacokinetics at the annual meeting of European Association for Study of Diabetes. XOMA 052 is a monoclonal antibody with the potential to improve treatment of patients with a wide variety of inflammatory diseases. The Berkeley, California-based company said Phase 1 studies would also examine certain markers of activity such as hemoglobin A1c and C-reactive protein of XOMA 052 and would enroll up to 72 Type 2 diabetes patients in total. Based on the Phase 1 Type 2 diabetes studies, XOMA plans to initiate clinical studies of XOMA 052 in rheumatoid arthritis, acute gout, and systemic juvenile idiopathic arthritis in 2008. The company said that either of the trials did not indicate any serious drug-related adverse events and that XOMA 052 was consistent with the human antibody with a terminal half-life of 15-21 days. The company said this drug profile, when combined with XOMA 052's high binding affinity of 300 femtomolar, could support potential dosing of once per month or longer in Type 2 diabetes patients. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.